Pathological Complete Response of HER2-Positive Breast Cancer to Trastuzumab and Chemotherapy Can Be Predicted by HSD17B4 Methylation

Identifying patients with HER2-positive breast cancer who would achieve pCR only by trastuzumab and chemotherapy may lead to surgery-free treatment.


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.